Evidence map›Paper›PMID 25618371›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2016

Recurrent amplification of MYC and TNFRSF11B in 8q24 is associated with poor survival in patients with gastric cancer.

Xiaohong Wang, Yiqiang Liu, Duanfang Shao, Ziliang Qian, Zhengwei Dong, Yun Sun, Xiaofang Xing, Xiaojing Cheng, Hong Du, Ying Hu and 13 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. C-Myc regulates PD-L1 expression in esophageal squamous cell carcinoma.American journal of translational research · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 1 country.

Xiaohong WangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Tissue Bank, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Yiqiang LiuDepartment of Pathology, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Duanfang ShaoDepartment of Surgery, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Ziliang QianAsia and Emerging Markets Innovative Medicine, AstraZeneca R&D, Shanghai, 201203, China.
Zhengwei DongAsia and Emerging Markets Innovative Medicine, AstraZeneca R&D, Shanghai, 201203, China.
Yun SunAsia and Emerging Markets Innovative Medicine, AstraZeneca R&D, Shanghai, 201203, China.
Xiaofang XingDepartment of Surgery, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Xiaojing ChengDepartment of Surgery, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Hong DuDepartment of Surgery, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Ying HuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Tissue Bank, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Yingai LiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Tissue Bank, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Lin LiDepartment of Surgery, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Bin DongDepartment of Pathology, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Ziyu LiDepartment of Surgery, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Aiwen WuDepartment of Surgery, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Xiaojiang WuDepartment of Surgery, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Zhaode BuDepartment of Surgery, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Xianglong ZongDepartment of Surgery, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Guanshan ZhuAsia and Emerging Markets Innovative Medicine, AstraZeneca R&D, Shanghai, 201203, China.
Qunsheng JiAsia and Emerging Markets Innovative Medicine, AstraZeneca R&D, Shanghai, 201203, China.
Xian-zi WenDepartment of Surgery, Peking University Cancer Hospital and Institute, Beijing, 100142, China. 13661176007@163.com.
Lian-hai ZhangDepartment of Surgery, Peking University Cancer Hospital and Institute, Beijing, 100142, China. zlhzlh@hotmail.com.
Jia-fu JiDepartment of Surgery, Peking University Cancer Hospital and Institute, Beijing, 100142, China. jiafuj@gmail.com.
Peking University · CNPeking University Cancer Hospital · CNShanghai Innovative Research Center of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGastric cancer (GC) is an aggressive malignancy whose mechanisms of development and progression are poorly understood. The identification of prognosis-related genomic loci and genes may suffer from the relatively small case numbers and a lack of systematic validation in previous studies.

methodsArray-based comparative genomic hybridization (aCGH) coupled with patient clinical information was applied to identify prognosis-related loci and genes with high-frequency recurrent gains in 129 GC patients. The candidate loci and genes were then validated using an independent cohort of 384 patients through branched DNA signal amplification analysis (QuantiGene assays).

resultsIn the 129 patients, a copy number gain of three chromosome regions-namely, 8q22 (including ESRP1 and CCNE2), 8q24 (including MYC and TNFRSF11B), and 20q11-q13 (including SRC, MMP9, and CSE1L)--conferred poor survival for patients. In addition, the correlation between the branched DNA signal amplification analysis results and the aCGH results was analyzed in 73 of these 129 patients, and MYC, TNFRSF11B, ESRP1, CSE1L, and MMP9 were found to be well correlated. Further validation using an independent cohort (n = 384) verified that only MYC and TNFRSF11B within 8q24 are related to survival. Patients with gains in both MYC and TNFRSF11B had poorer survival than those with no gains, particularly those with noncardia GC. Gains in both of these genes were also a significant independent prognostic indicator.

conclusionsOur results revealed that copy number gains in MYC and TNFRSF11B located at 8q24 are associated with survival in GC, particularly noncardia GC.

Indexed as

Chromosomes, Human, Pair 8Genes, mycAdultAgedAged, 80 and overCohort StudiesComparative Genomic HybridizationFemaleGene AmplificationGene DosageHumansMaleMiddle AgedOsteoprotegerinPrognosisStomach NeoplasmsOsteoprotegerinTNFRSF11B protein, human8q24Gastric cancerMYCSurvivalTNFRSF11B

Identifiers

PMID25618371
OpenAlexW2120326504

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.